Interstitial cystitis therapeutic - Jyong Biotech
Alternative Names: IC - Jyong BiotechLatest Information Update: 09 Jan 2026
At a glance
- Originator Jyong Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Interstitial cystitis
Most Recent Events
- 02 Dec 2025 Preclinical trials in Interstitial cystitis in Taiwan, USA (Intravesicular) (Jyong Biotech pipeline, December 2025)
- 02 Dec 2025 Preclinical trials in Interstitial cystitis in Taiwan, USA (IV) (Jyong Biotech pipeline, December 2025)